The US Food and Drug Administration (FDA) granted marketing approval to Clinuvel Pharma’s Scenesse (afamelanotide) to increase pain─free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria.
